After the hype around the potential Alzheimer's drug aducanumab and the subsequent bad news around approval and efficacy, the share price has largely come back. Now there is new positive news for Biogen and their drug for multiple sclerosis, Vumerity.

Biogen seems to be innovating and researching drugs for diseases that a lot of people would benefit from, but a lot of drug companies tend to keep their hands off, probably because of poor chances of success.

https://www.ema.europa.eu/en/medicines/human/summaries-opinion/vumerity